必威体育登录手机Agilent Technologies Supports Russell Thomas' Research at the Hamner Institutes for Health Sciences
SANTA CLARA, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec.6, 2011
必威体育登录手机Agilent Technologies Inc.必威体育登录手机(NYSE: A) and the Agilent Technologies Foundation today announced that Russell S.必威体育登录手机Thomas, Ph.D., of the Hamner Institutes for Health Sciences has been selected for an Agilent Thought Leader Award to support his work developing methods to predict drug-induced liver injury.
必威体育登录手机The award includes funding from the Agilent Technologies Foundation as well as instrumentation from the company, including a 6460 triple quadrupole LC/MS and an Agilent microarray scanner.
Dr.Thomas is director of the Institute for Chemical Safety Sciences at the Hamner, where researchers are applying a systems biology approach in an effort to predict drug-induced liver injury.This includes integration of data from transcriptomics, metabolomics, and genome-wide association studies.
Drug-induced liver injury is a primary reason regulators prohibit drugs or pull them off the market.One of the goals of Dr.Thomas' work is to eventually be able to identify patients with genetic susceptibility to liver damage from certain drugs.This could reduce injuries and even allow some previously banned drugs to be reintroduced.
"Drug-induced liver injury is a major problem in the development of safe and effective therapeutics," said Dr.Thomas."Current analyses of the genome sequence data of patients that have experienced drug-induced liver injury have failed to identify any susceptibility factors that are common across multiple drugs.必威体育登录手机I am grateful to receive the Agilent Thought Leader Award as an acknowledgment of the importance of the work we are conducting at the Hamner Institutes.The award will allow us to evaluate whether these susceptibility factors can be identified when the drugs are grouped based on the signaling pathways they activate in the liver and ultimately predict which patients may be at risk."
"The promise of personalized medicine is getting closer every day, and this is why we appreciate the opportunity to help make a real difference by supporting work like Dr.必威体育登录手机Thomas'," said Gustavo Salem, vice president and general manager of Agilent's Biological Systems Division.必威体育登录手机"We've been strong proponents of an integrated biology approach to solving important health problems for quite some time, and this research at the Hamner aligns well with Agilent's goals."
必威体育登录手机The Agilent Thought Leader Program promotes fundamental advances in the life sciences by contributing financial support, products and expertise to the research of thought leaders.
About The Hamner Institutes for Health Sciences
The Hamner Institutes for Health Sciences is a nonprofit research organization located in the heart of Research Triangle Park, N.C.The two flagship institutes at the Hamner, the Institute for Chemical Safety Sciences and the Hamner-UNC Institute for Drug Safety Sciences, build upon 37 years of preeminent research in toxicology and human health research to develop and validate new cutting-edge tools for safety assessment.The Hamner continues to grow its open, multidisciplinary campus through global partnerships with academia, industry and government, and remains dedicated to positively impacting human health.For more information, please visithttp://www.thehamner.org.
必威体育登录手机About Agilent Technologies
必威体育登录手机Agilent Technologies Inc.(NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications.The company's 18,700 employees serve customers in more than 100 countries.必威体育登录手机Agilent had net revenues of $6.6 billion in fiscal 2011.必威体育登录手机Information about Agilent is available at必威体育登录手机www.dayu-jc.com.
# # #
For images related to this press release,
please visit the
ImageLibrary (Image #199)
Contact:
必威体育登录手机Stuart Matlow, Agilent
+1 408 553 7191
必威体育登录手机stuart_matlow@agilent.com
Erin Smith, MMI Public Relations for the Hamner Institutes
+1 919 233 6600
erin@mmipublicrelations.com